Rheumatoid Arthritis: Newer Treatment Modalities

  • Muharrem Gokcem Life Sciences Foundation Research Laboratories Minneapolis, Minnesota, United States of America
  • Barbara Gokcen Life Sciences Foundation Research Laboratories Minneapolis, Minnesota, United States of America
Keywords: Treatment of rheumatoid arthritis, Nonsteroidal anti-inflammatory drugs, Penicillamine, Hybrid rheumatoid arthritis

Abstract

DOI: http://dx.doi.org/10.5915/15-4-12431

With the introduction of the newer nonsteroidal anti-inflammatory drugs (NSAIDs) and penicillamine, our therapeutic armamentarium for the rheumatoid disease group had been significantly broadened. ln addition, there has been a renewed interest in anti-malarials, the use of some immunosuppressive agents, and plasmapheresis. The purpose of this article is to offer a helpful therapeutic scheme in the selection of these newer anti-rheumatoid agents.

Furthermore, we have attempted to incorporate the clinical and laboratory profiles of rheumatoid patients into the treatment scheme. Rheumatoid arthritis can be divided into three subgroups: seronegative rheumatoid arthritis, sero-positive rheumatoid arthritis, and hybrid rheumatoid arthritis. Such classification offers a guideline in selecting the most suitable anti-arthritic agents.

This paper was presented at the 16 annual oonvention of the Islamic Medical Association of North America, September 2-5, 1983.

Author Biographies

Muharrem Gokcem, Life Sciences Foundation Research Laboratories Minneapolis, Minnesota, United States of America

M.D., Ph .D.

Life Sciences Foundation Research Laboratories

Minneapolis, Minnesota, United States of America
Barbara Gokcen, Life Sciences Foundation Research Laboratories Minneapolis, Minnesota, United States of America

M.D.

Life Sciences Foundation Research Laboratories

Minneapolis, Minnesota, United States of America
Published
1983-10-09
Section
Review Articles